BioSpace News Archive

New agreement builds on 20-plus-year relationship, helping Premier partners streamline processes and improve the patient experience [04-February-2020] EXTON, Pa. , Feb. 4, 2020 /PRNewswire/ -- Premier , a healthcare improvement company, has signed a group purchasing agreement with Ricoh USA , Inc. to create frameworks for streamlined, pre-negotiated, discounted do

PTU Elite: CSPT® Prep Program Supports Growing Need for Highly-Trained, Sterile-Compounding-Certified Pharmacy Technicians and Promotes Commitment to Medication Safety [04-February-2020] DENVER , Feb. 4, 2020 /PRNewswire/ -- TRC® Healthcare (Therapeutic Research Center or TRC®), a leading provider of medication advisory and learning solutions and the author of Phar

The Delta Dental of Virginia Foundation is excited to announce that it has awarded nearly $400,000 to 50 organizations across the Commonwealth to fund research, educational outreach and other programs designed to improve the oral and overall health of Virginians.

Data continue to support potential of once-weekly VIP analogue for adults with pulmonary arterial hypertension

Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, announced that Dan Chevallard, Chief Financial Officer of Viracta, will present a company overview at the 2020 BIO CEO and Investor Conference on Tuesday, February 11, 2020 at 2:30 pm ET in New York, NY.

Halo Communications, a leading clinical communication and collaboration platform provider for health systems, announces the hiring of healthcare IT industry veteran, Kurt Hammond as Chief Growth Officer.

Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, granted 17 newly-hired employees options to purchase an aggregate of 168,250 shares of Akebia’s common stock on January 31, 2020, as inducements material to each such employee’s entering into employment with Akebia.

Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that Dr. Steven M. Fruchtman, President and Chief Executive Officer, will present a company update at the BIO CEO & Investor Conference February 10-11, 2020.

Inato, a platform that helps biopharmaceutical companies increase the pool of available patients engaged in clinical trials, announced it has raised a $14 million Series A round of venture capital financing.

Heska Corporation, a provider of advanced veterinary diagnostic and specialty products, plans to report its fourth quarter and full year 2019 financial performance in a press release on Tuesday, February 25, 2020 before the market opens, and to host an earnings call to discuss the results following the release at 9 a.m. MT / 11 a.m. ET..